- Home
- SEED vs HOTH Comparison
SEED vs HOTH Comparison
Compare SEED & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | HOTH |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.7M |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SEED | HOTH |
|---|---|---|
| Price | $1.13 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 18.7K | ★ 2.9M |
| Earning Date | 01-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.49 |
| 52 Week High | $2.49 | $2.12 |
Technical Indicators
Market Signals| Indicator | SEED | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 43.78 |
| Support Level | $1.05 | $0.49 |
| Resistance Level | $1.21 | $0.80 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 10.71 | 7.69 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).